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Abstract
Objectives: The study was designed to characterize the surface, core promoter, precore/core region sequences for the
presence of mutations in hepatitis B virus (HBV) associated with different liver diseases.
Methods: 567 HBV associated patients with different liver diseases were enrolled in this study. All samples were analyzed for
HBV surface, core promoter, precore/core region mutations and genotypes using PCR and direct sequencing.
Results: HBV genotype D (72.8%) was the predominant type followed by genotype A (27.2%). The serum viral load of HBV
was highest in HBsAg carriers group and lowest in patients with hepatocellular carcinoma. 17.9% patients with cirrhosis and
24.6% hepatocellular carcinoma cases were ADV-resistant with rtA181T/V mutations in the S-gene. A1896T was found more
frequently in fulminant hepatic failure compared to acute viral hepatitis patients (p=0.038). T1753V mutation was
significantly higher in patients with cirrhosis of liver (34.6%) than in chronic hepatitis (18.9%) and hepatocellular carcinoma
patients (21.2%; p=0.001). T1762/A1764 mutation was observed in all the groups. C1914G core gene mutation was
associated with the hepatocellular carcinoma (32.2%) compared to other groups. HBV genotype D predominated in
comparison to genotype A. An increased frequency of precore mutation and BCP double mutations amongst the
population studied was also observed.
Conclusion: Mutations such as T1762/A1764, T1753V and C1914G were usually associated with advanced forms of liver
disease and had an increased risk of HCC. The nucleotide variability in the basal core promoter and precore regions possibly
plays a role in the progression of HBV disease. Prospective studies on the sequence variations of the preC/C region of the
HBV genome and the molecular mechanisms in relation to progression of liver disease would aid in better understanding of
the biological significance of HBV strains in India.
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Introduction
Hepatitis B virus (HBV) infection is one of the most important
infectious diseases worldwide and is a major global health
problem. Approximately one million people die annually because
of acute and chronic HBV infection despite the availability of
effective vaccines and effective antiviral medications [1]. HBV
replicates via the reverse transcriptase enzyme system which lacks
proofreading ability; therefore, new virions possess diverse genetic
variability [2]. Different election pressures such as host immunity
(endogenous pressure), and vaccine or antiviral agents (exogenous
pressure) influence the production of HBV quasispecies in infected
individuals. It has been demonstrated that mutations in the HBV
genome not only impact the replication fitness of the virus
(phenotypical effect) but can also influence the disease outcome, as
well as the response to treatment (clinical effect) [3]. Mutations in
the HBV surface (S), precore (PC) and basal core promoter (BCP)
genes are observed frequently in HBV infected patients, and
studies show that these mutations are associated with the clinical
outcomes of HBV disease [4], [5]. The most clinically relevant
mutations in the S region arise in the immunologic ‘‘a de-
terminant’’ domain and neutralizing antibodies (anti-HBs) are
targeted against this epitope [6]. The basic core promoter (BCP, nt
1742–1849) and its adjacent precore (preC) region are crucial for
replication of HBV. BCP binds various liver factors and preC
forms e structure in pregenomic RNA (pgRNA) as the encapsida-
tion signal [7]. Changes in viral replication may influence the
progression of liver diseases, particularly in fulminant hepatitis and
acute exacerbation of chronic hepatitis [8], [9]. Mounting
evidence has emerged to demonstrate that BCP and preC mutants
are predisposed to severe and progressive liver diseases after HBV
infection, causing an increased risk for hepatocellular carcinoma
(HCC) [10], [11], [12]. For instance, mutations T1762/A1764
and A1899 have been reported to be independent risk factors for
HCC [13], and T1653 and/or V1753 mutations are believed to
promote the process of liver degradation [14]. However, the
association of these mutations with severe symptoms is manifested
in certain populations but not in others [15], [16], [17].
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AStudies have shown that G1896A is involved in HBeAg
negativity by introducing a stop codon in the preC region [18].
Although the T1762/A1764 double mutation, commonly occur-
ring in HBeAg-negative patients, was observed in vivo to suppress
the production of preC mRNA independent of G1896A, recent in
vitro research suggested other single site substitutions rather than
these two which may be responsible for the reduction of HBeAg
expression [9], [19].Unknown mutation in this core promoter may
impede the seroconversion of HBeAg during antiviral treatment
[20].
The prevalence of hepatitis B surface antigen (HBsAg) in India
varies from 1–13%, with an average of 4.7% [21], [22]. Without
any organized HBV prevention programme, and with 25 million
live births each year, nearly 1 million HBV infections are added to
the HBV pool yearly, contributing to its rapid expansion [23]. In
this situation, HBV epidemiology is presumed to be an important
determinant of the global HBV burden in the future. Molecular
epidemiological data regarding HBV infection provides informa-
tion about the emerging worldwide epidemiology of HBV, which
is likely to shift its focus to South Asia in general, and India in
particular, in the years to come, in view of the growing HBV
burden therein and in the absence of interventions.
In a recent Indian study, a substantial proportion of anti-HBe
positive chronically infected individuals continued to circulate
preC wild-type HBV [24], and also documented an HBeAg
positive CHB patient with a pre-C mutant. Further more
a substantial proportion of anti-HBe positive subjects carry the
precore wild-type strain, which suggests that predominance of pre-
C mutants can never be solely responsible for the absence of
HBeAg [25]. The HBV profile of Indian patients, a zone of
intermediate prevalence, is believed to be an important de-
terminant of the global HBV burden in the near future. The
present study was designed to detect and characterize mutations in
the precore/core and surface genes of the hepatitis B virus using
direct sequencing, and its association with clinical outcome in
HBV infected patients in different stages of liver disease.
Materials and Methods
Patients
Five hundred sixty seven HBsAg-positive patients comprising of
115 Acute Viral Hepatitis (AVH) patients, 40 patients of
Fulminant Hepatic failure (FHF), 100 HBsAg carriers (ASC),
116 chronic hepatitis patients (CH), 78 patients with liver cirrhosis
(LC) and 118 patients with hepatocellular carcinoma (HCC) and
admitted in the wards of Lok Nayak hospital, New Delhi, were
enrolled in the study from march 2003 till February 2006. All
patients were interviewed and examined by gastroenterologists to
evaluate the clinical findings and the results of the investigations
(liver histology, ultrasonography, and laboratory tests such as
serology, biochemical tests and virological markers) in order to
determine the clinical status of the patient. AVH was diagnosed
when patients exhibited overt jaundice and/or increased alanine
aminotransferase levels (at least 3 times above the normal value)
documented at least twice at a 1-week interval without any history
of pre-existing liver disease [26]. FHF was considered to exist
when, after a typically acute onset, the patient become deeply
jaundiced and went into hepatic encephalopathy within 8 weeks of
onset of the disease, with no past history of chronic hepatitis [27].
The patients with CH and liver cirrhosis were diagnosed by
histopathological criteria laid down by International Study Group
on Chronic Hepatitis [28]. The diagnosis of underlying cirrhosis
was based on clinical, histological, endoscopic (presence of varices),
and radiological documentation [ultrasound (US) and CT scan].
Histological evidence was used wherever available. All patients
with HCC enrolled in the study were diagnosed, based on either
pathological or cytological examination or an elevated /-
fetoprotein level ($400 ng/ml) combined with at least one positive
image on angiography, sonography and/or computerized tomog-
raphy. Cases were enrolled only if they met the EASL diagnostic
criteria for HCC [29]. Written consent was obtained from each
participant before inclusion in the study. Sera from patients with
different liver diseases were obtained once the diagnosis was made.
Serum samples were collected from all inpatients and outpatients
with different stages of HBV-linked hepatic diseases and stored at
–70uC until analysis. Ethical review board of Maulana Azad
Medical College, New Delhi, had approved the study protocol.
Serological and Biochemical Parameters
All patients were tested for HBV serological markers (HBsAg,
anti-HBs, IgM/IgG anti-HBc and HBeAg), hepatitis C virus (anti-
HCV) and hepatitis A virus and hepatitis E virus using
commercially available kits (DIA PRO Diagnostic Bioprobes,
Srl., Italy). Patients with co-infections patients (HIV, HDV and
HCV) were excluded from the study. Liver function tests such as
serum albumin, total bilirubin, ALT, AST and ALP were
measured by an auto-analyzer.
DNA Extraction from Serum
DNA was extracted from 200 mI of serum samples using
QIAmp DNA mini-extraction kit (Qiagen K.K., Tokyo, Japan).
The extracted DNA was dissolved in 50 ml of TE buffer.
Amplification of Precore/core Gene
For sequence analysis, nested PCR for amplification of Precore/
core was performed. For the first stage PCR, 25 ml of reaction
mixture containing 2 ml of the DNA sample, 1X PCR buffer
(10 mM tris-HCl, pH 9.0, 50 mM KCl, 1.5 mM MgCl2, 0.01%
gelatin and 0.1% triton X-100), 10 mM of each dNTP, 100 ng of
each outer primer and 1U of Taq DNA polymerase was amplified
in a thermal cycler (Perkin-Elmer Cetus, Norwalk, CT) for 35
cycles. Each cycle entailed denaturation at 95uC for 60s, primer
annealing at 55uC for 30s and extension at 72uC for 60s with final
extension step at 72uC for 10 min. After the first amplification,
1 ml of the PCR products was re-amplified for another 35 cycles
with 100 ng of each inner primer.
For the Precore/core region, the outer sense primer was 59-
CTGGGAGGAGTTGGGGGA-39, nucleotide positions 1770–
1787; the outer antisense primer was 59-CAATGCTCAGGA-
GAC TCTAA-39, nucleotide positions 2476–2495; the inner sense
primer was 59-GGTCTTTG TACTCGGAGGCT-39, nucleotide
positions 1788–1808; the inner antisense primer was 59-GTCA-
GAAGGCAAAAAAGA GA-39, nucleotide positions 2467–2486.
Amplification of Basal Core-promoter (BCP) and Surface
Gene
For the first stage PCR, 25 ml of reaction mixture containing
2 ml of the DNA sample, 1X PCR buffer (10 mM tris-HCl,
pH 9.0, 50 mM KCl, 1.5 mM MgCl2, 0.01% gelatin and 0.1%
triton X-100), 10 mM of each dNTP, 100 ng of each outer primer
and 1U of Taq DNA polymerase was amplified in a thermal cycler
(Perkin-Elmer Cetus, Norwalk, CT) for 35 cycles. Each cycle
entailed denaturation at 95uC for 60 s, primer annealing at 52uC
for 30 s and extension at 72uC for 60 s with final extension step at
72uC for 10 min. After the first amplification, 1 ml of the PCR
products was re-amplified for another 35 cycles with 100 ng of
each inner primer. For the basal core-promoter, the outer sense
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positions 1282–1301; the outer antisense primer was 59-
CACAGCTTGGAGGCTT GAAC-39, nucleotide positions
1881–1862; the inner sense primer was 59-CTCATCTGCCGGA
CCGTGTG-39, nucleotide positions 1342–1361; the inner anti-
sense primer was 59-TAGGACAT GAACAAGAGATG-39, nu-
cleotide positions1840–1859. For the surface gene amplification,
the outer sense primer was (HB1: 369–388) 59-ATCGCTG-
GATGTGTCTGCGG-39 and the outer anti-sense primer was
(HB2:1136–1155) 59-GGCAACGGGGTAAAGGTTCA-39. The
inner sense primer was (HB3: 822–842) 59-TTAGGGTT-
TAAATGTATACCC-39 and the inner anti-outer sense primer
was (HB4: 427–448) 59-CATCTTCTTGTTGGTTCTTTCTG-
39, respectively.
Direct Nucleotide Sequencing
The PCR products were sequenced twice in forward and
reverse directions using the inner primer pair of surface gene and
precore/core genes. The nucleotide sequences of the amplified
products were directly determined using fluorescence-labelled
primers with a 3100 Automatic Sequencer (Applied Biosystems,
Foster City, CA, USA). Sequencing conditions were specified in
the protocol for the Taq DyeDeoxy Terminator Cycle Sequencing
Kit (Applied Biosystems). (Representative samples submitted in the
Genbank are as follows: EF158128-EF158294, DQ328773-
DQ328791 and DQ184651-DQ184670.
Statistical Evaluation
Data were expressed as means 6 standard deviations (SD).
Statistical analyses were performed using a Chi square test and
Fisher’s exact test for categorical variables and Mann-Whitney’s U
test or one-way analysis of variance for continuous variables, as
appropriate. Differences were considered significant for p values
less than 0.05. The statistical analysis software used was SPSS
software, version 12.0.
Results
Clinical and Demographic Data
Based on the clinical and laboratory findings the patients were
divided into five categories which include 115 patients of AVH, 40
patients of FHF, 116 patients of CH, 78 patients with LC and 118
patients of HCC. Also 100 HBsAg carriers were inducted as
controls. The clinical and laboratory findings (serologic, bio-
chemical and virological profile) of AVH and CH are summarized
in Table 1 and 2. Amino acid sequences of a portion of the S
region of all 567 isolates of the study patients were compared with
the amino acid sequences retrieved from the GenBank as reference
genes. Only HBV genotype D and A were detected in all the study
samples, which were respectively distributed in 72.8% and 27.2%
of the total samples.
Characteristics of Nucleotide Substitution in the Surface
Region of HBV related Different Liver Disease Patients
Amino acid mapping reveals that the S region was relatively
conserved; however, an important substitution of P120T/S was
observed in 7.8% (9/115) of AVH and 11.2% (13/116) in CH
patients. Some substitutions such as P127T, V128A and D144N
were observed in the immunologic domain of the ‘‘a determinant’’
region. No G145R substitution was identified in any of the isolates.
In the S gene, an A184V mutation was found in 17.9% of the
cirrhotic and 24.6% HCC patients included in this study,
respectively. Among the patients of LC, SW172stop (6.4%) and
SL173F (4.2%) mutations were also detected.
The Clinical, Biochemical and Virological Profile of HBV
Related Acute and Fulminant Hepatitis Patients
Table 1, compares the clinical and virological characteristics
between patients with AVH and FHF. The mean age of AVH
patients was 32.09615.73 yeas and that of FHF patients was
29.08610.7, respectively. Male predominance was observed
amongst AVH and FHF cases. Levels of AST, ALT, Total
Bilirubin and alkaline phosphatase were significantly higher in
patients with FHF compared to AVH. Distribution of HBV
genotypes was no different between patients with FHF (genotype
D accounted for 72.5% & genotype A- 27.5%) and AVH
(genotype D accounted for 67.8% & genotype A- 32.2%), and
the difference was statistically non-significant (p=0.724). Mean
HBV DNA levels were comparable in patients with AH and FHF
(3.561.45 Vs. 3.761.28 log copies/ml; NS).
We compared our core promoter mutation data with previously
reported HBV sequences [13]. Mutations at nt. 1762 and 1764
and 1766 and nt. 1753 were found when they were compared with
each respective prototype sequence. The numbers of patients with
T1762/A1764 are shown in Table 1. There was no difference in
the frequency of these mutations between patients with FHF and
those with AVH (32/115 (27.8%) v 15/40 (37.5%); NS). Double
mutation T1764/G1766 was found only in 3/40 (7.5%) patients of
FHF (Table 1). The numbers of patients with C/A/G 1753
mutation are higher in FHF group (7/40; 17.5%) compared to
AVH group (6/115; 5.2%; p=0.040). Mutation in the precore
region, the number of AVH and FHF patients with A1896 is
shown in Table 1. A1896 was found more frequently in patients
with FHF compared to patients with AVH (p=0.038). Other
precore mutations were G1899A and C1914G which were
comparable in AVH and FHF patients. A1993T and T2077C
mutations were only found in FHF cases (Table 1).
The Clinical, Biochemical and Virological Profile of HBV
Related Chronic Liver Diseases
The demographic, virological, and clinical characteristics of the
patients with different stages of chronic HBV infection are
summarized in Table 2. Male patients predominated in different
stages of chronic HBV infection. The male-to-female ratio was
lower in the asymptomatic carrier group than in the CH, Cirrhosis
and HCC groups, respectively. The serum levels of ALT, AST and
T. Bil were significantly higher in the Chronic hepatitis group than
those in the other groups (p,0.05). Among all patients, the
prevalence of HBeAg decreased gradually with clinical spectrum
types from ASC (76.0%; 76/100), CHB (62.1%; 72/116), LC
(37.2%; 29/78) and HCC (22.9%; 27/118). The highest serum
viral load of HBV was observed in the ASC group, and a markedly
lower viral load was found in the HCC group. The majority of
patients belonged to genotype D (306/412; 74.3%), with 75.0%
(75/100) in the ASC group, 69.8% (81/116) in the CH group,
73.1% (57/78) in the LC group, and 78.8% (93/118) in the HCC
group. Although, genotype D was most common in each group, no
statistically significant differences were found in the distribution of
genotypes in various stages of chronic HBV infection. Genotype A
was found in 25.7% (106/412) cases of various stages of CH
infection (Table 2).
The HBV DNA sequences bearing the core promoter/precore/
core regions were successfully amplified and following nucleotide
substitutions were observed among studied strains (Table 3).
Analysis of the nucleotide at position 1753 showed that a T-to-V
(A/G/C) mutation was significantly higher in LC (34.6%) in
comparison with CH (18.9%) and HCC (21.2%) (p=0.001),
suggesting that this mutation could be an indicator of liver
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mutation or an independent mutation, were significantly higher in
LC and HCC than CH and ASC (Table 2). Particularly, the
double mutation (T1762/A1764) was found in 20.7%, 38.5% and
44.9% of CH, LC and HCC, respectively (p,0.001) and the
difference was significant. The frequency of 1896 mutation was
significantly high among CH, LC and HCC with respect to ASC
(p,0.05).However, there was no difference in the percentage of
patients with precore mutations between the HCC group (37.3%)
compared with that of CH (24.1%) and LC (32.1%), respectively.
The prevalence of the A1899 substitution was also higher in HCC
(19.5%), LC (23.1%) and CH (14.7%) than in ASC (7.0%).
Further, the C1914G core gene mutation was associated with the
HCC cases (32.2%) compared to ASC (5.0%), CHB (7.8%) and
LC (10.3%), respectively. No significant differences were observed
in other mutations prevalent among the studied strains.
The clinical features of HBeAg-positive patients and anti-HBe-
positive patients are shown in Table 3. Based on the HBeAg
serology status, 205 patients were HBeAg positive and 362 patients
were HBeAg-negative. There was no significant difference in age,
ALT, AST, and bilirubin levels (biochemical parameters), and
HBV viral load between HBeAg-positive and HBeAg-negative
groups; however, a significant difference in the gender distribution
was observed (p=0.001) (Table 3). Majority of chronic hepatitis B
patients with HCC were HBeAg negative and were older than the
other groups. The rate of precore 1896 mutant and core 1914
mutants were significantly higher (p=0.001) in HBeAg-negative
patients (43.4% and 23.4%) compared to HBeAg-positive patients
(11.9% and 4.7%), respectively. There was no significant
difference in the rate of BCP (T1762/A1764) double mutation
between HBeAg-positive and HBeAg-negative patients (Table 3).
Discussion
Many studies have shown that virus mutations, including
mutations of surface, BCP, and precore are linked to the severity
and outcome of HBV infection. In the present study, amino acid
mapping of the S gene showed a high rate of homology between
the sequences. It has been shown that amino acid substitutions
within the ‘‘a determinant’’ domain in the HBV S region may lead
to conformational changes in the S protein. Some of these changes
may create important medical and public health problems
including vaccine escape, failure of hepatitis B immune globulin
(HBIG) to protect liver transplant patients and babies born to
HBV carrier mothers, and failure to detect HBV carriers with
certain diagnostic tests [30]. In this study, the P120T/S was the
most important substitution. This substitution was located at the
Table 1. The clinical, biochemical and virological profile of HBV related patients.
Acute Viral Hepatitis
(N=115)
Fulminant Hepatitis
(N=40)
Chronic Hepatitis
(N=116)
Liver Cirrhosis
(N=30)
Hepatocellular
Carcinoma (N=30)
Age (Mean 6SD) 32.09615.73 29.08610.7 33.35614.25 46.24615.02 51.60615.27
Sex (M/F) 1:1.1 0.8:1 1.9:1 6:1 9:1
ALT (IU/L) 280.616568.58 1106.96989.94 80.70675.04 95.38697.32 82.86664.36
AST (IU/L) 219.396415.154 1154.661245.70 76.25671.84 76.08660.73 64.20645.96
ALP (IU/L) 88.306123.63 267.706193.68 39.50661.53 89.556135.33 202.606196.01
T. Bil. (mg/dL) 2.7861.38 5.6862.67 0.9660.24 1.260.49 1.660.82
HBsAg 115 40 116 30 30
Anti-HBc 115 40 116 30 30
HBeAg positive 43 19 37 10 12
HBV DNA
(log copies/mL)
3.561.45 3.761.28 4.961.59 5.361.92 6.8362.05
Abbreviations: ALT:Alanine Transaminases; AST:Aspartate Transaminases;
ALP:Alkaline Phosphatases; T. Bil.:Total Bilirubin.
HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen.
doi:10.1371/journal.pone.0039028.t001
Table 2. Characteristics of patients with hepatitis B virus (HBV) infection according to hepatitis B e antigen (HBeAg) status.
Characteristics HBeAg-positive (N=121) Anti-HBe-positive (N=210) P
Age (yr; mean 6 SD) 35.06612.8 38612.2 NS
Sex : Male/Female 95 (78.5)/26 (21.5) 194 (92.4)/16 (7.6) 0.001
ALT (IU/L) 67.3656.7 86.36105.9 0.066
AST (IU/L) 64.8689.2 81.5692.8 0.110
T-Bil (mg/dL) 1.2760.86 1.5961.81 0.0684
Genotype A/D 32 (26.5)/89 (73.5) 43 (20.5)/167 (79.5) 0.211
HBV DNA (log copies/mL) 6.3965.4 5.1767.08 0.1019
Abbreviations: ALT:Alanine Transaminases; AST:Aspartate Transaminases;
ALP:Alkaline Phosphatases;T. Bil.:Total Bilirubin.
doi:10.1371/journal.pone.0039028.t002
Clinical Implications of Liver Diseases
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39028outside of the ‘‘a determinant’’ immunologic domain. The
P120T/S was detected in 7.8% of chronic hepatitis and 11.2%
in patients with cirrhosis. As previously reported, the P120T/S
substitution may cause problems with diagnostic assays, and may
also cause vaccine escape and poor response to HBIG therapy
[31]. Drug resistant mutations to ADV have been reported mainly
in the HBV polymerase domain D rtN236T or the domain B
rtA181V/T [32], [33], whereas a domain D rtN236T mutation
does not overlap with the envelope gene, a mutation at rtA181T
can result in a stop mutation in the envelope region of the S gene
(SW172stop). In addition, an ADV-resistant mutation at rtA181V
results in a concomitant change at SL- 173F. The S gene
mutation, A184V, was detected in the ADV resistant rtA181T/V
chronic hepatitis. This mutation site overlaps with the rt192 region
in the polymerase gene. However, the A184V mutation did not
result in amino acid changes in the polymerase region. There is
one published report that the A184V mutation was related to
reduced or negative HBsAg signal [34]. In our study, however,
changes in HBsAg titer were not observed. The clinical
implications of this remains to be determined. We detected
sW172stop (6.4%) and sL173F (4.2%) mutations in LC patients
with ADV-resistant rtA181T/V polymerase mutations. A large
percentage of the cases with rtA181T mutations developed
SW172stop mutations. In cases with ADV treated LMV-resistant
mutations, the rtA181T mutation was reported at the ADV
treatment baseline with low HBV DNA titers [35].
HBeAg negative patients with HBV DNA had significantly
more severe liver disease than in other groups, suggesting that the
accumulation of mutations due to host immune pressure in the due
course of viral persistence could lead to the progression of liver
damage. It is unlikely that the severity of illness is dependent solely
on the prevailing precore/core sequence; it probably relates to
such other factors like viral load, host immune response, etc. Some
studies have also shown association of mutation in the preC/C
region with the severity of liver disease [17]. A recent study from
India has shown that chronic and fulminant hepatitis B is not
associated with precore or core HBV mutants [24]. However,
several studies have reported association between the severity of
liver disease and the occurrence of A1896 mutations [36, [37],
[38] and A1896 mutant has been detected frequently in HBeAg-
negative asymptomatic carriers [39], [40]. In this study, there was
no correlation between the presence of A1896 mutation and the
presence of cirrhosis or elevated transaminase coinciding with
previous reports of a lack of correlation between this mutation and
liver disease [41], [42]. Thus, A1896 mutation alone appears to
have no direct pathogenic role.
The prevalence of mutations at nt.1762 and 1764 in the core
promoter and nt.1896 in the precore region increased propor-
tionately with increased disease severity in patients with acute
HBV infection. Thus, our results indicate that mutations in the
core promoter and precore regions, together or independently, are
associated with fulminant or severe acute hepatitis and that HBV
strains with such mutations cannot direct the production of
HBeAg. A low prevalence of HBeAg or anti-HBe in patients with
fulminant and severe acute hepatitis B has been also noted. The
precore mutant variants have also been reported in HBeAg-
positive patients, ranging from 0%–80% [5], [43]. The BCP
T1762/A1764 double mutations located at the HBV X gene
diminishes HBeAg production, and is associated with more active
liver disease [2], [44].
It is well known that the double mutation (T1762/A1764) in
BCP is associated with an increased risk of liver disease. For
instance, the frequency of double mutation (T1762/A1764)
increased with advancing clinical status in Taiwanese patients
(3%, 11%, 32% and 64% in ASC, LC, CH, and HCC groups,
respectively) [45]. A recent report from China has also demon-
strated that the incidence of double mutation increased along with
the progression of liver disease; the percentage of the double
mutation was 33%, 56% and 85% in CH, LC, and HCC groups,
respectively [46]. In Indian patients, however, the T1762/A1764
double mutation was increased in CH from 20.7% to 38.5% in LC
and 44.9% in HCC (Table 2). In the present study, detection of
BCP double mutation T1762/A1764 was high in patients of FHF,
LC and HCC, respectively; and had shown association with
advanced form of liver diseases. Moreover, no significant
difference (p=0.866) was observed between the frequency of
BCP double mutation in patients with HBeAg positive and
HBeAg-negative phenotypes. Other studies have also shown
a relationship between BCP double mutations and the clinical
manifestations of HBV infection [5], [47]. In addition, analysis of
the nucleotide at position 1753 showed that a T-to-V (A/G/C)
mutation increased to 34.6% in LC from 18.9% in CH, but
dramatically decreased in HCC (21.2%; Table 2), suggesting that
this mutation is associated with liver cirrhosis rather than HCC. In
contrast, analysis of sera or plasma from Japanese subjects with
AC, CH, LC and HCC infected with HBV genotype C showed
that the percentage of T1753V mutation increased with pro-
gression of liver disease [Takahashi et al., 1999]. It is also reported
that T1753V mutation was higher in HCC (53.2%) compared
with LC (18.8%) and CH (9.8%) [45]. These results were
inconsistent with the present study, particularly in LC and
HCC. These discrepancies might be due to the reason that most
Table 3. Prevalence of Precore, Core and Surface region mutations in HBV isolated among different clinical groups.
Mutations
Acute Viral Hepatitis
(N=115)
Fulminant
Hepatitis (N=40)
Chronic Hepatitis
(N=116)
Liver Cirrhosis
(N=30)
Hepatocellular
Carcinoma (N=30) Total %
T1753C/G 7 (7.1) 2 (5.0) 22 (18.9) 10 (33.3) 14 (46.7) 55 (16.6)
A1762T/G1764A 32 (27.8) 15 (37.5) 39 (33.6) 14 (46.7) 20 (66.7) 120 (36.3)
T1764/G1766 0 (0.0) 3 (7.5) 24 (20.7) 4 (13.3) 11 (36.7) 42 (12.7)
G1896A 20 (17.4) 18 (45.0) 38 (32.7) 12 (40.0) 17 (56.6) 105 (31.7)
G1899A 13 (12.2) 10 (25.0) 39 (33.6) 16 (53.3) 13 (43.3) 101 (30.5)
C1914G 2 (1.7) 6 (15.0) 12 (10.3) 7 (23.3) 19 (47.5) 46 (13.9)
A1993T 0 (0.0) 1 (2.5) 13 (11.2) 4 (13.3) 8 (26.7) 26 (7.8)
T2077C 0 (0.0) 3 (7.5) 23 (19.8) 8 (26.7) 7 (23.3) 41 (12.4)
doi:10.1371/journal.pone.0039028.t003
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genotype C, whereas most of samples in the present study were
HBV genotype D.
Our data also showed that viral mutations at nt. 1753 was more
frequently observed in FH patients with fulminant hepatitis than in
patients with acute hepatitis. T to C/A/G mutations at nt. 1753
was reported to be closely associated with progression of CH.
These mutations were found in AT rich regions of the core
promoter and can change the binding efficiency of transcription
and translation factors.
The present study suggests that HBV genotype D and A were
detected most frequently in HBV associated liver disease patients
in India, and genotype D was predominant. There was an
increased frequency of precore mutation and BCP double
mutations amongst the patients studied. The study indicates that
core mutations can be frequently detected in patients with chronic
HBV infection. It was observed that HBV genotype, as well as the
serotype, may not be associated with an increased risk of HCC.
The T1762/A1764 and T1753V mutations in BCP could be one
of the indicators for progression of liver disease in India.
Prospective studies on the sequence variations of the preC/C
region of the HBV genome and the molecular mechanisms in
relation to progression of liver disease would provide better
understanding of the biological significance of HBV strains in
India.
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